Catalent announced on April 6, 2022 that it has acquired Vaccine Manufacturing and Innovation Centre UK Limited’s biologics development and manufacturing facility currently under construction near Oxford, United Kingdom. Catalent plans to invest up to US$160 million (£120 million) into the completion of the construction of the facility.
The focus of the facility will be to develop and manufacture biologic therapies and vaccines, including messenger RNA, proteins, and other advances modalities. The facility is expected to employ more than 400 people once completed as well as support public and private organizations looking to develop and manufacture biotherapeutics.
